CLAIMS

1. A compound of formula **I**:



I

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is hydrogen or halogen;

R^2 is substituted or unsubstituted cycloalkyl;

each occurrence of R^3 is independently halogen, alkyl, $-(CH_2)_mOR^4$, $-(CH_2)_mSR^4$, $-(CH_2)_mN(R^4)_2$, $-(CH_2)_mNR^4C(O)R^4$, $-(CH_2)_mNR^4C(O)N(R^4)_2$, $-(CH_2)_mNR^4CO_2R^4$, $-(CH_2)_mCO_2R^4$, $-(CH_2)_mC(O)R^4$, $-(CH_2)_mC(O)N(R^4)_2$, $-(CH_2)_mOC(O)N(R^4)_2$, $-(CH_2)_mS(O)_2R^4$, $-(CH_2)_mSO_2N(R^4)_2$, $-(CH_2)_mS(O)R^4$, $-(CH_2)_mNR^4SO_2N(R^4)_2$, $-(CH_2)_mNR^4SO_2R^4$, $-(CH_2)_mC(=S)N(R^4)_2$, wherein m is 0, 1 or 2 and R^4 is hydrogen or alkyl;

r is 0, 1 or 2; and

n is 0, 1 or 2.

2. The compound of claim 1, wherein R^1 is hydrogen or fluorine; R^2 is substituted or unsubstituted cycloalkyl; r is 0 or 1; R^3 is alkyl, or $-(CH_2)_mOR^4$, wherein m is 0, 1 or 2 and R^4 is hydrogen or alkyl; and n is 0, 1 or 2.

3. The compound of claim 1, wherein R^2 is substituted or unsubstituted norbornyl and compounds have the formula **II**:



II

wherein R^1 is hydrogen or halogen;

each occurrence of R^3 is independently halogen, alkyl, $-(CH_2)_mOR^4$, $-(CH_2)_mSR^4$, $-(CH_2)_mN(R^4)_2$, $-(CH_2)_mNR^4C(O)R^4$, $-(CH_2)_mNR^4C(O)N(R^4)_2$, $-(CH_2)_mNR^4CO_2R^4$, $-(CH_2)_mCO_2R^4$, $-(CH_2)_mC(O)R^4$, $-(CH_2)_mC(O)N(R^4)_2$, $-(CH_2)_mOC(O)N(R^4)_2$, $-(CH_2)_mS(O)_2R^4$, $-(CH_2)_mSO_2N(R^4)_2$, $-(CH_2)_mS(O)R^4$, $-(CH_2)_mNR^4SO_2N(R^4)_2$, $-(CH_2)_mNR^4SO_2R^4$, $-(CH_2)_mC(=S)N(R^4)_2$, wherein m is 0, 1 or 2 and R^4 is hydrogen or alkyl;

n is 0, 1 or 2;

r is 0, 1 or 2;

each occurrence of R^5 is independently halogen, alkyl, $-(CH_2)_qOR^6$, $-(CH_2)_qSR^6$, $-(CH_2)_qN(R^6)_2$, $-(CH_2)_qNR^6C(O)R^6$, $-(CH_2)_qNR^6C(O)N(R^6)_2$, $-(CH_2)_qNR^6CO_2R^6$, $-(CH_2)_qCO_2R^6$, $-(CH_2)_qC(O)R^6$, $-(CH_2)_qC(O)N(R^6)_2$, $-(CH_2)_qOC(O)N(R^6)_2$, $-(CH_2)_qS(O)_2R^6$, $-(CH_2)_qSO_2N(R^6)_2$, $-(CH_2)_qS(O)R^6$, $-(CH_2)_qNR^6SO_2N(R^6)_2$, $-(CH_2)_qNR^6SO_2R^6$, $-(CH_2)_qC(=S)N(R^6)_2$, wherein q is 0, 1 or 2, and each occurrence of R^6 is independently hydrogen or alkyl; and

p is 0, 1 or 2.

4. The compound of claim 1, wherein R^2 is substituted or unsubstituted cyclohexyl and compounds have the formula **III**:



III

wherein R^1 is hydrogen or halogen;

each occurrence of R^3 is independently halogen, alkyl, $-(CH_2)_mOR^4$, $-(CH_2)_mSR^4$, $-(CH_2)_mN(R^4)_2$, $-(CH_2)_mNR^4C(O)R^4$, $-(CH_2)_mNR^4C(O)N(R^4)_2$, $-(CH_2)_mNR^4CO_2R^4$, $-(CH_2)_mCO_2R^4$, $-(CH_2)_mC(O)R^4$, $-(CH_2)_mC(O)N(R^4)_2$, $-(CH_2)_mOC(O)N(R^4)_2$, $-(CH_2)_mS(O)_2R^4$, $-(CH_2)_mSO_2N(R^4)_2$, $-(CH_2)_mS(O)R^4$, $-(CH_2)_mNR^4SO_2N(R^4)_2$, $-(CH_2)_mNR^4SO_2R^4$, $-(CH_2)_mC(=S)N(R^4)_2$, wherein m is 0, 1 or 2 and R^4 is hydrogen or alkyl;

n is 0, 1 or 2;

r is 0, 1 or 2;

each occurrence of R^5 is independently hydrogen, halogen, alkyl, $-(CH_2)_qOR^6$, $-(CH_2)_qSR^6$, $-(CH_2)_qN(R^6)_2$, $-(CH_2)_qNR^6C(O)R^6$, $-(CH_2)_qNR^6C(O)N(R^6)_2$, $-(CH_2)_qNR^6CO_2R^6$, $-(CH_2)_qCO_2R^6$, $-(CH_2)_qC(O)R^6$, $-(CH_2)_qC(O)N(R^6)_2$, $-(CH_2)_qOC(O)N(R^6)_2$, $-(CH_2)_qS(O)_2R^6$, $-(CH_2)_qSO_2N(R^6)_2$, $-(CH_2)_qS(O)R^6$, $-(CH_2)_qNR^6SO_2N(R^6)_2$, $-(CH_2)_qNR^6SO_2R^6$, $-(CH_2)_qC(=S)N(R^6)_2$, wherein q is 0, 1 or 2 and each occurrence of R^6 is independently hydrogen or alkyl; and

p is 0, 1 or 2.

5. The compound of claim 1, wherein R^1 is F.

6. The compound of claim 1, wherein R^1 is H.

7. The compound of claim 1, wherein r is 0 or r is 1 and R^3 is alkyl, OH, CH_2OH, or alkoxy.

8. The compound of claim 1, wherein n is 0.

9. The compound of claim 1, wherein n is 1.

10. The compound of claim 1, wherein n is 2.

11. The compound of claim 3, wherein p is 0.

12. The compound of claim 4, wherein p is 0.

13. The compound of claim 4, wherein p is 1.

14. The compound of claim 4, wherein p is 2.

15. The compound of claim 3 or 4, wherein p is 0 or 1 and R^5 is OH, or alkyl.

16. The compound of claim 3, wherein R^1 is F or H; p is 0; n is 0 or 1; r is 0 or 1; and R^3 is OH, CH_2OH, alkyl or alkoxy.

17. The compound of claim 4, wherein R^1 is F or H; p is 0, 1 or 2; each occurrence of R^5 is independently alkyl, OH, CH_2OH or alkoxy; n is 0 or 1; r is 0 or 1; and R^3 is OH, CH_2OH, alkyl or alkoxy.

18. The compound of claim 1, wherein the compound has one of the following structures:



I-1



I-2



I-3



I-4



I-5



I-6



I-7



I-8



I-9



I-10



I-11



I-12



I-13



I-14



I-15



I-16



I-17



I-18





I-19 **I-20**

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

20. The composition according to claim 19, further comprising an additional therapeutic agent selected from a treatment for stroke, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder.

21. A method of treating a neurodegenerative, neurological, ischemic or inflammatory disorder comprising administering a therapeutically effective amount of a compound of claim 1.

22. The method according to claim 21, wherein the ischemic disorder is stroke.

23. The method according to claim 22, comprising the further step of :
administering to said patient an additional therapeutic agent selected from a treatment for stroke, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor,

an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.